Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
19 Feb 2024
19 Feb 2024
Historique:
revised:
11
12
2023
received:
20
11
2023
accepted:
05
02
2024
medline:
19
2
2024
pubmed:
19
2
2024
entrez:
19
2
2024
Statut:
aheadofprint
Résumé
Reports of DILI due to herbal and dietary supplements have been increasing over time. To characterise clinical, laboratory and histopathological phenotypes and outcomes of drug-induced liver injury (DILI) due to anabolic-androgenic steroids (AAS), selective androgen receptor modulators (SARMs), and bodybuilding supplements (BBS) in Australia. Retrospective case series. Patients presented to nine Australian tertiary hospitals, 2017-2023. DILI was defined biochemically and patients were included if their treating physician attributed DILI to preceding use of AAS, SARMs or BBS. Primary endpoint was time to normalisation of liver biochemistry. Secondary endpoints were hospitalisation for investigation or management of DILI, death attributable to liver injury, and liver transplantation. Twenty-three cases of DILI were identified, involving 40 drugs: 18 AAS, 14 SARMs and eight BBS. Patients were predominantly male (22/23), with median age 30 years (IQR 26-42). Most were symptomatic (21/23). Median latency of onset was 58 days (IQR 28-112 days) from drug commencement. Most patients (17/23) were admitted to hospital. Based on updated Roussel Uclaf Causality Assessment Method, DILI was possible in 17/23, probable in 2/23 and unlikely in 4/23. Median time to normalisation of liver biochemistry was 175 days (IQR 70-292 days) from presentation. Three (3/23) were treated with corticosteroids, 14/23 were treated for itch, and one (1/23) underwent liver transplantation. There were no deaths. The prognosis of DILI from AAS, SARMs and BBS is good although liver transplantation may rarely be required. A detailed drug history is important in uncovering DILI due to these supplements.
Sections du résumé
BACKGROUND
BACKGROUND
Reports of DILI due to herbal and dietary supplements have been increasing over time.
AIMS
OBJECTIVE
To characterise clinical, laboratory and histopathological phenotypes and outcomes of drug-induced liver injury (DILI) due to anabolic-androgenic steroids (AAS), selective androgen receptor modulators (SARMs), and bodybuilding supplements (BBS) in Australia.
METHODS
METHODS
Retrospective case series. Patients presented to nine Australian tertiary hospitals, 2017-2023. DILI was defined biochemically and patients were included if their treating physician attributed DILI to preceding use of AAS, SARMs or BBS. Primary endpoint was time to normalisation of liver biochemistry. Secondary endpoints were hospitalisation for investigation or management of DILI, death attributable to liver injury, and liver transplantation.
RESULTS
RESULTS
Twenty-three cases of DILI were identified, involving 40 drugs: 18 AAS, 14 SARMs and eight BBS. Patients were predominantly male (22/23), with median age 30 years (IQR 26-42). Most were symptomatic (21/23). Median latency of onset was 58 days (IQR 28-112 days) from drug commencement. Most patients (17/23) were admitted to hospital. Based on updated Roussel Uclaf Causality Assessment Method, DILI was possible in 17/23, probable in 2/23 and unlikely in 4/23. Median time to normalisation of liver biochemistry was 175 days (IQR 70-292 days) from presentation. Three (3/23) were treated with corticosteroids, 14/23 were treated for itch, and one (1/23) underwent liver transplantation. There were no deaths.
CONCLUSIONS
CONCLUSIONS
The prognosis of DILI from AAS, SARMs and BBS is good although liver transplantation may rarely be required. A detailed drug history is important in uncovering DILI due to these supplements.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60:1399-1408.
Nash E, Sabih AH, Chetwood J, Wood G, Pandya K, Yip T, et al. Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. Med J Aust. 2021;215:261-268.
Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68:87-95.
Machek SB, Cardaci TD, Wilburn DT, Willoughby DS. Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: a narrative review. Steroids. 2020;164:108753.
U.S. Food Drug Administration. FDA in brief: FDA warns against using SARMs in body-building products. FDA; 2017. Accessed September 2023. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-body-building-products
Flores JE, Chitturi S, Walker S. Drug-induced liver injury by selective androgenic receptor modulators. Hepatol Commun. 2020;4:450-452.
Yaramada P, Goyal P, Hammami M, Cai C. RAD-140: an emerging cause of drug-induced liver injury. Am J Gastroenterol. 2020;115:S1273-S1274.
Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-induced liver injury. ACG Case Rep J. 2020;7:e00370.
Bedi H, Hammond C, Sanders D, Yang HM, Yoshida EM. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J. 2021;8:e00518.
Niedfeldt MW. Anabolic steroid effect on the liver. Curr Sports Med Rep. 2018;17:97-102.
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an endocrine society scientific statement. Endocr Rev. 2014;35:341-375.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806-815.
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17:14.
Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139:876-887.
World Health Organisation Classification of Tumours Editorial Board. World Health Organisation classification of tumours: digestive system tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
Mohamed WT, Jahagirdar V, Fatima I, Ahmed MK, Jaber F, Wang K, et al. Selective androgen receptor modulators (SARMs)-induced liver injury: a case report and review of literature. Cureus. 2023;15:e35094.
Vignali JD, Pak KC, Beverley HR, DeLuca JP, Downs JW, Kress AT, et al. Systematic review of safety of selective androgen receptor modulators in healthy adults: implications for recreational users. J Xenobiot. 2023;13:218-236.
Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7:84-94.
Australian Criminal Intelligence Commission. Illicit drug data report 2018-19. Canberra City: Commonwealth of Australia; 2020. Accessed September 2023. https://www.acic.gov.au/publications/illicit-drug-data-report/illicit-drug-data-report-2018-19
Chalasani N, Reddy KRK, Fontana RJ, Barnhart H, Gu J, Hayashi PH, et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians. Am J Gastroenterol. 2017;112:1382-1388.
Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, Stephens C, García-Cortes M, García-Muñoz B, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015;41:116-125.
Abeles RD, Foxton M, Khan S, Goldin R, Smith B, Thursz MR, et al. Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. BMJ Open Gastroenterol. 2020;7:e000549.
Romano A, Grassia M, Esposito G, Petrillo M, Pezzella M, Romano FM, et al. An unusual case of left hepatectomy for focal nodular hyperplasia (FNH) linked to the use of anabolic androgenic steroids (AASs). Int J Surg Case Rep. 2017;30:169-171.
Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, et al. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. Liver Int. 2011;31:348-353.
Stolz A, Navarro V, Hayashi PH, Fontana RJ, Barnhart HX, Gu J, et al. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Aliment Pharmacol Ther. 2019;49:1195-1204.
U.S. Food Drug Administration. FDA analysis shows body-building products labeled to contain steroid and steroid-like substances continue to inflict serious liver injury. FDA; 2017. Accessed September 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-analysis-shows-body-building-products-labeled-contain-steroid-and-steroid-substances-continue
Trinh S, Batt N, Sawhney R, Nicoll A. The importance of prospective drug-induced liver injury registries. Liver Int. 2023;43:2323-2324.